Biocause Pharma(SZ:000627) 证券时报·2025-08-08 15:38Core Viewpoint - *ST Tianmao announced the decision to voluntarily terminate its stock listing on the Shenzhen Stock Exchange and will apply to transfer to the National Equities Exchange and Quotations (NEEQ) after delisting [1] Group 1: Company Announcement - On August 8, *ST Tianmao's board approved the proposal to terminate its stock listing [1] - The stock is set to resume trading on August 11, 2025, after the delisting process [1] Group 2: Financial Reporting Issues - *ST Tianmao is currently facing a delisting crisis due to its failure to disclose the 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - As of August 6, the company had not yet disclosed its financial reports, and it is working to complete the necessary documentation [6] Group 3: Company Background - *ST Tianmao operates as an investment holding company primarily through its subsidiaries, Guohua Life and Huari Insurance [6] - Guohua Life, established in 2007, has total assets of 271.599 billion and net assets of 26.22 billion as of June 2023 [6] Group 4: Stock Performance - Since July 8, *ST Tianmao's stock has dropped over 40%, currently priced at 1.45 yuan per share, with a total market capitalization of 7.1 billion [6] - Recently, the stock has shown signs of recovery with a two-day increase of over 4% [6]